Profound Medical (TSE:PRN) Trading Down 2.1% - Here's What Happened

Key Points

• Profound Medical Corp. saw its stock price drop by 2.1% on Monday, trading between C$5.59 and C$5.63.
• The company's market capitalization is C$169.20 million, with a negative PE ratio of -3.88 and significant liquidity indicated by a quick ratio of 14.98.
• Profound Medical develops incision-free therapeutic systems for the image-guided ablation of diseased tissue, with its lead product being the TULSA-PRO system.

Profound Medical Corp. (TSE:PRN - Get Free Report) shares were down 2.1% during mid-day trading on Monday . The company traded as low as C$5.59 and last traded at C$5.63. Approximately 17,464 shares were traded during trading, an increase of 119% from the average daily volume of 7,990 shares. The stock had previously closed at C$5.75.

Profound Medical Stock Up 0.9%

The company has a debt-to-equity ratio of 20.05, a current ratio of 6.12 and a quick ratio of 14.98. The business has a 50 day moving average price of C$7.09 and a 200 day moving average price of C$7.64. The firm has a market capitalization of C$166.79 million, a P/E ratio of -3.83 and a beta of -0.25.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.